Gilead Sciences Shares Outstanding 2010-2024 | GILD

Gilead Sciences shares outstanding for the quarter ending December 31, 2024 were 1.255B, a 0.24% decline year-over-year.

  • Gilead Sciences 2024 shares outstanding were 1.255B, a 0.24% decline from 2023.
  • Gilead Sciences 2023 shares outstanding were 1.258B, a 0.32% decline from 2022.
  • Gilead Sciences 2022 shares outstanding were 1.262B, a 0% decline from 2021.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Gilead Sciences Shares Outstanding 2010-2024 | GILD

  • Gilead Sciences 2024 shares outstanding were 1.255B, a 0.24% decline from 2023.
  • Gilead Sciences 2023 shares outstanding were 1.258B, a 0.32% decline from 2022.
  • Gilead Sciences 2022 shares outstanding were 1.262B, a 0% decline from 2021.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.9B
Amgen (AMGN)$158.1B
Vertex Pharmaceuticals (VRTX)$121.1B
Bristol Myers Squibb (BMY)$111.6B
CSL (CSLLY)$80.7B
GSK (GSK)$75.7B
Regeneron Pharmaceuticals (REGN)$75B
Argenex SE (ARGX)$38.9B
Alnylam Pharmaceuticals (ALNY)$32.4B
BioNTech SE (BNTX)$28.7B
BeiGene (ONC)$23.2B
Biogen (BIIB)$20B
Illumina (ILMN)$16.3B
Insmed (INSM)$15B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.4B
Moderna (MRNA)$13.8B
Intra-Cellular Therapies (ITCI)$13.7B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.5B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Bio-Techne Corp (TECH)$10.4B
Vaxcyte (PCVX)$10.4B
Sarepta Therapeutics (SRPT)$10.2B
Exelixis (EXEL)$9.8B
Ascendis Pharma (ASND)$9.4B
Exact Sciences (EXAS)$9.3B
Bio-Rad Laboratories (BIO.B)$8.7B
QIAGEN (QGEN)$8.7B
Repligen (RGEN)$8.4B